Each capsule contains pomalidomide as the active ingredient
Pomide belongs to anti-cancer therapy of Oncology Division.
A thalidomide analogue indicated, in combination with dexamethasone, for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.